Cigna Group（CI）の決算・業績分析
Cigna Groupの2025年有価証券報告書をAI分析。売上高$274.9B(+11.2%)。営業利益$9.2B。Financials。
目次
Cigna Groupの2025年度 業績サマリー
Cigna Group（証券コード: CI）の2025年度決算・業績分析。売上高は$274.9B（前年比+11.2%）。営業利益は$9.2B（前年比-2.3%）。純利益は$6.0B（前年比+57.7%）。有価証券報告書を基に、業績変化の要因・リスク・見通し・セグメント構成を AI が分析しました。
Cigna Groupの2024年度 注目ポイント
※ 直近の2025年度XBRLデータは取込済みですが、AI分析は2024年度の10-Kを対象としています。
- Net income surged 25.1% YoY to $6.8B (XBRL), driven by improved profitability and cost management.
- Revenue grew 3.7% YoY to $180.5B (XBRL), with operating income rising 6.4% to $8.4B (XBRL).
- Free cash flow reached $11.8B (XBRL), while $7.6B was returned to shareholders via share repurchases (XBRL).
- ROE of 14.7% (XBRL) and ROIC of 6.4% (XBRL) highlight strong capital efficiency.
Cigna Groupの売上高変化の要因
- •Total revenue increased 3.7% YoY to $180.5B (XBRL), with growth driven by pharmacy revenues ($185.36B), premiums ($45.996B), and fees ($14.79B) (10-K). Historical data shows a 5-year revenue CAGR of 32.0% (XBRL), rising from $48.6B in FY2020 to $180.5B in FY2024. Operating income grew 6.4% YoY to $8.4B (XBRL), reflecting revenue expansion and cost control.
Cigna Groupの営業利益変化の要因
- •Operating margin improved to 4.7% (XBRL) and net margin to 3.8% (XBRL), with net income rising 25.1% YoY to $6.8B (XBRL). Operating income growth was supported by revenue gains and efficiency improvements (10-K). Gross profit data is not available (XBRL). SG&A expenses increased by $22M YoY (10-K), though R&D expenses are not disclosed.
Cigna Groupの事業リスクと対応
Strategic/operational execution risks: Failure to implement initiatives could harm growth and financial performance (10-K).
Industry competitiveness: Rapid healthcare structure changes may reduce market share and client retention (10-K).
Differentiation challenges: Inability to stand out from competitors could weaken profitability (10-K).
Regulatory/technological shifts: Legislative changes, telehealth/AI adoption, and drug pricing trends pose operational risks (10-K).
Drug access and cost: Fluctuations in drug pricing and generic/biosimilar market dynamics risk profitability (10-K).
Cigna Groupの今後の見通し・業績予想
Cigna Groupの事業内容
Cigna Group operates as a global health company through two platforms: Evernorth Health Services and Cigna Healthcare (10-K). It generates revenue from pharmacy benefit services, specialty care, U.S. healthcare, and international health segments. Key segments include Evernorth (pharmacy and specialty services), Cigna Healthcare (U.S. and international health), and Other Operations. The company serves 182 million customer relationships across 30+ countries with no significant customer concentration (10-K). Competitive advantages include clinical expertise, value-focused solutions, and innovation, though specific intellectual property is not disclosed (10-K).
Cigna GroupのAI業績分析レポート（2024年度）
Cigna Group (CI) FY2024 Annual Report Analysis
Highlights
Business Overview
Cigna Group operates as a global health company through two platforms: Evernorth Health Services and Cigna Healthcare (10-K). It generates revenue from pharmacy benefit services, specialty care, U.S. healthcare, and international health segments. Key segments include Evernorth (pharmacy and specialty services), Cigna Healthcare (U.S. and international health), and Other Operations. The company serves 182 million customer relationships across 30+ countries with no significant customer concentration (10-K). Competitive advantages include clinical expertise, value-focused solutions, and innovation, though specific intellectual property is not disclosed (10-K).
Revenue Analysis
Total revenue increased 3.7% YoY to $180.5B (XBRL), with growth driven by pharmacy revenues ($185.36B), premiums ($45.996B), and fees ($14.79B) (10-K). Historical data shows a 5-year revenue CAGR of 32.0% (XBRL), rising from $48.6B in FY2020 to $180.5B in FY2024. Operating income grew 6.4% YoY to $8.4B (XBRL), reflecting revenue expansion and cost control.
Profitability Analysis
Operating margin improved to 4.7% (XBRL) and net margin to 3.8% (XBRL), with net income rising 25.1% YoY to $6.8B (XBRL). Operating income growth was supported by revenue gains and efficiency improvements (10-K). Gross profit data is not available (XBRL). SG&A expenses increased by $22M YoY (10-K), though R&D expenses are not disclosed.
Balance Sheet Analysis
Equity ratio stood at 30.3% (XBRL), with total equity of $46.2B (XBRL) as of FY2024. Debt-to-equity ratio was 2.30x (XBRL), and liquidity was strong with $7.8B in cash (XBRL). Current ratio of 0.77x (XBRL) suggests potential short-term liquidity challenges. ROA of 4.4% (XBRL) and ROIC of 6.4% (XBRL) reflect asset and capital efficiency.
Cash Flow Analysis
Operating cash flow increased to $8.7B (XBRL), exceeding net income due to working capital adjustments and non-cash items (10-K). Free cash flow reached $11.8B (XBRL), with $7.6B allocated to share repurchases (XBRL) and $357M in dividends (XBRL). Investing cash flow was $3.1B (XBRL), though CapEx and major acquisitions/divestitures are not specified.
Risks
Outlook
Management highlights revenue growth from pharmacy and premium segments, along with improving net income as key trends for future results (10-K). No specific forward-looking guidance is provided in the 10-K or XBRL data.
Historical Time Series
| Metric | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | 48.6B | 153.6B | 160.4B | 174.1B | 180.5B | 195.3B |
| Operating Income | 4.2B | 8.1B | 8.2B | 7.9B | 8.4B | 8.5B |
| Net Income | 2.6B | 5.1B | 8.5B | 5.4B | 6.8B | 5.2B |
| Total Assets | 155.8B | 155.5B | 154.9B | 143.9B | 152.8B | 155.9B |
| Total Equity | 45.3B | 50.3B | 47.1B | 44.7B | 46.2B | 41.0B |
| Operating Cash Flow | 3.8B | 9.5B | 10.3B | 7.2B | 8.7B | 11.8B |
Financialsの企業一覧
Cigna Groupと同じ「Financials」セクターの企業